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A 28-day repeated dose study in rats (OECD407) enhanced for
endocrine and immune parameters was performed with hexabro-
mocyclododecane (HBCD). Rats were exposed by daily gavage to
HBCD dissolved in corn oil in 8 dose groups with doses ranging
between 0 and 200 mg/kg bw per day (mkd). Evaluation consisted
of dose-response analysis with calculation of a benchmark dose
at the lower 95% one-sided confidence bound (BMDL) at prede-
fined critical effect sizes (CESs) of 10–20%. The most remark-
able findings were dose-related effects on the thyroid hormone
axis, that is, decreased total thyroxin (TT4, BMDL 55.5 mkd at
CES  10%), increased pituitary weight (29 mkd at 10%) and
increased immunostaining of TSH in the pituitary, increased
thyroid weight (1.6 mkd at 10%), and thyroid follicle cell activa-
tion. These effects were restricted to females. Female rats also
showed increased absolute liver weights (22.9 mkd at 20%) and
induction of T4-glucuronyl transferase (4.1 mkd at 10%), sug-
gesting that aberrant metabolization of T4 triggers feedback
activation of the thyroid hormone system. These effects were ac-
companied by possibly secondary effects, including increased
cholesterol (7.4 mkd at 10%), increased tibial bone mineral density
( > 49 mkd at 10%), both in females, and decreased splenocyte
counts (0.3–6.3 mkd at 20%; only evaluated in males). Overall,
female rats appeared to be more sensitive to HBCD than male
rats, and an overall BMDL is proposed at 1.6 mkd, based on a 10%
increase of the thyroid weight, which was the most sensitive
parameter in the sequence of events.
Key Words: hexabromocyclododecane; brominated flame re-
tardants; endocrine disruption; thyroid hormones; rats; hazard
identification; risk assessment.
Hexabromocyclododecane (HBCD) is a brominated flame
retardant (BFR) which has its main application in textile
industry and in polystyrene foam for building construction
(Hutzinger and Thoma, 1987). The compound is simply
blended with polymers and, therefore, more likely to leach
out of products than covalently bound flame retardants. Indeed,
HBCD has been identified as a contaminant of environmental
significance (Letcher and Behnisch, 2003). In aquatic biota in
polluted areas, levels of HBCD are comparable to other BFRs,
such as tetrabromobisphenol-A and some polybrominated
biphenylethers (Morris et al., 2004; Sellstrom et al., 2003),
although the production volume of HBCD is lower than of
those other BFRs. Low but significant exposure levels of this
potentially persisting and bioaccumulating compound are
found in humans with a fluctuating increase over time
(Fa¨ngstro¨m et al., 2006; Ryan et al., 2006). Intake via food is
possibly the largest source of human HBCD exposure, although
inhalation and dermal routes may contribute significantly,
notably, in occupational exposure (KEMI, 2003). Therefore,
the use of this compound is a reason for environmental and
health concern (Alaee et al., 2003).
The current toxicological database on HBCD is too limited
to form a solid basis for an integrated risk assessment, com-
bining data from effect and exposure studies in multiple species
and environmental levels (Letcher and Behnisch, 2003). HBCD
has been tested in a 28-day toxicity study in rats showing a
lowest observed effect level of 125 mg/kg on the basis of liver
weight effects, but no hormonal parameters were addressed
(Chengelis, 1997; cited in KEMI, 2003). In a 90-day toxicity
study, also in rats, liver weight increases were found at
100 mg/kg and higher without observed pathology. In addi-
tion, there were effects on the thyroid hormone axis, that is,
decreased T4 and increased TSH (Chengelis, 2001; cited in
KEMI, 2003). Furthermore, in mice, HBCD induced develop-
mental neurotoxic effects (Eriksson et al., 2006). Additional
studies are needed to understand effects and risks of exposure
to this compound in wildlife, humans, and their ecosystems,
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that is, to understand mechanisms of toxicity and/or biological
effects and to identify risk of exposure (Darnerud, 2003).
Therefore, the current subacute oral dose study was under-
taken in rats, with a focus on endpoints commonly affected by
persistent organic pollutants, that is, in the immune and endo-
crine domains, including effects on the thyroid hormone (TH)
axis, on hematology, on bone size and mineralization, and on
retinoid parameters (Andrews et al., 2001). So far, in line with
the observations mentioned above, the TH system has been iden-
tified as a target for potential endocrine disruptive hazard of
BFRs in general (Legler and Brouwer, 2003). Interaction of
BFRs with the TH system was mainly described at the level
of TH metabolism; several BFRs inhibit TH sulfation, modulate
deiodination, and induce glucuronidase and uridine diphosphate
(UDP) glucuronyl transferase. Further BFR interactions with the
TH system are known at the level of transport, for example,
competition with T4 on transthyretin (TTR), thus possibly facil-
itating transport over the placenta and the blood-brain barrier.
The rationale to test the endocrine effects of HBCD in the
in vivo model in this study was supported by results from
in vitro tests with indicator cell lines sensitive to endocrine
activity, which showed that HBCD can interact with multiple
hormone systems, particularly with TH-mediated cell pro-
liferation and with progesterone receptors, and to a lesser
extent with estrogen, androgen, and dioxin (arylhydrocarbon)
receptors (Hamers et al., 2006), while significant enhancement
of TH-receptor (TR)–mediated gene expression was confirmed
in HeLa TR cells (Yamada-Okabe et al., 2005).
ANIMALS, MATERIALS, AND METHODS
Forty Wistar rats (RIVM Cpb:WU) of both sexes, aged 7 weeks, were
purchased from the RIVM breeding facilities (three to four generations after
original purchase from HsdCpb:WU Harlan, Horst, NL) and housed individually
to allow recording of individual feed consumption, and to avoid bias from
hierarchical stress. Housing was in plastic Macrolon cages of appropriate sizes
with stainless steel wire cover and chopped wood bedding. Light/dark regime
was 12/12 h. Standard pelleted rat feed without soy (RMH-GS, Hope Farms/
ABDiets, Woerden, NL; this standardized formulation contains ca 18,800 IU
vit.A/kg) and drinking water were supplied ad libitum. HBCD (technical
mixture containing traces of tetra- and pentabromocyclododecane) was obtained
as a composite mix through Bromine Science and Environmental Forum (BSEF,
with kind cooperation of Dr Klaus Rothenbacher). The technical preparation is
a mixture of three enantiomers, HBCD-a, -b, and -c, and their respective
proportion in the used batch was 10.28, 8.72, and 81.01%. It was dissolved in
corn oil via primary solution in acetone, which was evaporated afterward. Target
dosing was 0, 0.3, 1, 3, 10, 30, 100, and 200 mkd; the highest dose depended on
maximum HBCD solubility in corn oil. Appropriate concentrations of HBCD in
corn oil were based on daily gavage of 5 ml/kg bw.
The experimental protocol followed the OECD407 28-day subacute toxicity
guideline, which was enhanced for endocrine and immunological endpoints
(Andrews et al., 2001). However, in contrast to the published protocol, the
animals were distributed among more dose groups each with fewer animals,
that is, five rats per sex per dose group, for improved assessment of dose-
response relationships (Kavlock et al., 1996; Slob, 2002).
Exposure started at the age of 11 weeks. Animals were inspected daily for
general condition and clinical abnormalities. Beddings were changed weekly, at
which time rats were submitted to in-hand observations and reaction to
handling, and their body weight and feed consumption was recorded.
At the end of the exposure period, animals were necropsied in the course of
5 days, resulting in a total of 28–33 days of exposure. Necropsies were
performed in a targeted manner to avoid clustering of animals from single
exposure groups on one day and to allow clustered immunological analysis
which was only performed in males to avoid variability due to the estrous cycle.
Targeted necropsy of females in the first day of diestrous was abandoned
because staging of the estrous cycle on the basis of vaginal smears was not
completely consistent with further histological staging of uterus and vagina
epithelium. Euthanasia was achieved by exsanguination from the abdominal
aorta under carbon dioxide anesthesia.
During necropsy, blood was collected and the following organs were dis-
sected: skin/mammary gland, liver, pancreas, spleen, thymus, heart, lungs, stom-
ach, duodenum, ileum, jejunum, colon, ceacum, ovaries, uterus, urine bladder,
kidney, adrenals, trachea/thyroid gland, brain, pituitary gland, testes, epididy-
mis, seminal vesicles with coagulation gland, prostate, popliteal lymph nodes,
ischiadic nerve, fat, muscle, bone marrow (from femur), sternum, and thoracic
spine. All organs were visually inspected and weighed directly after dissection or
after fixation (thyroid, pituitary) to reduce mechanical damage. Sperm was
collected from the cauda epididymis for direct analysis of motility and mor-
phology. Defined samples of the liver, intestines, brain, adrenals, testes, ovaries,
muscle, and fat were snap frozen in liquid nitrogen and stored at 80C. Plasma
aliquots were stored at  20C. A sample of whole blood and part of the spleen
were freshly analyzed. All remaining dissected organs were fixed in standard
formalin for further histological processing. In these collected tissues, the
following endpoints were addressed: sperm quantity and quality (cauda epidi-
dymis sperm), cellular composition (blood, bone marrow), immune cell subpop-
ulations and natural killer (NK) activity (spleen), thyroid hormones (plasma),
clinical plasma components (plasma), HBCD kinetics (liver, fat), metabolic
activity (liver), and histopathology (all prepared tissues/organs). A distal body
preparation, including lumbar vertebrae, pelvic bones, and one intact hind limb,
was frozen at  20C for later dissections and analysis of bone parameters.
Experiments were approved by the institutional Committee on Animal
Experimentation, according to Dutch legislation.
Compound analysis. Internal dosing was verified by analysis of HBCD
enantiomers in liver of three animals per dose group and in a limited number of
fat samples. Liver was chosen because sufficient material is available for
analysis of measurable quantities of the compound and potentially also of
metabolites. The liver sample (about 100 mg) was weighed, dried with sodium
sulphate (Merck, Darmstadt, Germany), and stored for 2 h. The dried sample
was extracted using a Soxhlet apparatus with hexane:acetone (3:1, vol/vol,
Promochem, Wesel, Germany), with a starting volume of 100 ml. After extrac-
tion, 1 ml of 13C-labeled a-, b-, c-HBCD (100 ng/ml, CIL, Andover, MA) was
added, and the extracts were evaporated to 10 ml. An aliquot of the extract (1/10)
was dried with nitrogen to determine the lipid content gravimetrically. The
residual extract was treated with 1 ml concentrated sulfuric acid (Merck) to
remove the lipids. This step was two times repeated, and the combined hexane
extract was further purified with silica gel. Silica gel was eluted with 11 ml
isooctane and 29 ml isooctane:diethyl ether (85:15, vol/vol, Promochem).
Finally, the silica eluate was evaporated to almost dryness with nitrogen, and
1 ml of methanol was added. The a-, b-, c-HBCD diastereomers were deter-
mined with LC-MS/MS (LCQ Advantage, Thermo Finnigan, Austin, TX) using
electrospray ionization. Identification of HBCD was based on the retention times
of the 13C-labeled compounds and the bromine clusters of the adduct ion m/z
677 and fragment ion m/z 644. The m/z 644 ion was used for quantification. A
Zorbax Eclipse XDB-C18 HPLC column (2.13 150 mm, 3.5 lm, Agilent, Palo
Alto, CA) was used with a gradient of ammonium chloride (0.1mM) and
acetonitrile (ACN) starting from 0 to 6 min at ammonium chloride:ACN (3:1,
vol/vol); followed by ammonium chloride:ACN (1:9, vol/vol) from 6 to 10 min.
Measurement of the HBCD-b enantiomer in a selected number of tissue
samples showed that this isomer only comprised a minor fraction of the total
HBCD (< 1.5%; data not shown); measurements in the full experimental set
were therefore restricted to the HBCD-a and -c enantiomers.
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HBCD partitions to adipose tissue (Yu and Atallah, 1980; cited in KEMI,
2003), therefore, internal concentrations in the liver in this study are expressed
on lipid basis.
Organ weights. The relationship between organ weight and body weight in
a growing animal is allometric of nature for most organs with allometric
constants that vary by organ and also by stage of organ ontogeny (Trieb et al.,
1976). Analysis of relative organ weights does not eliminate the indirect effect
of treatment on organ weight via its effect on body weight and was even
suggested to be unreliable (Shirley, 1977; Trieb et al., 1976). Furthermore,
changes in body fat, muscularity, or bone density, all potential specific effects
of endocrine disruption, may confound the conclusions of relative organ
weights. To avoid this as well as complex and/or uncommon approaches such as
to adjust each organ weight by its specific allometric exponent of the body
weight, or to differentiate between organs for the specific use of body or brain
as a reference, or to use body weight as a covariate (Bailey et al., 2004; Trieb
et al., 1976), analysis of organ weights was restricted to independent dose-
response analysis of absolute organ weights. The observed organ weight
changes were then interpreted in the context of concomitant other changes,
particularly of body weight but also of other organs.
Histology. After fixation (and subsequent weighing, see above), organs
sampled for histology were dehydrated and paraffinized and embedded
according to standard sampling and trimming procedures. Sections of 4 lm
were stained with hematoxylin and eosin in an automated way. Microscopic
observations were done by comparison of control and exposed samples.
Scoring thyroid gland histopathology was done by semiquantitative assessment
of parameters of thyroid activation (follicular cell size, nuclear size,
vacuolization), and of follicle size, without knowledge of treatment. For each
parameter, four relative stages were discerned (control, slight, moderate, and
severe). Effects on TSH in thyrotropic cells in the adenohypophysis were
assessed by immunohistochemistry. For this purpose, paraffin sections of
routinely processed, formalin fixed, pituitaries were deparaffinized in a graded
series of xylol/ethanol. Endogenous peroxidase activity was blocked in a 1/1
methanol/distilled water solution with 1/100 0.3% H2O2 added. Antigen
exposure was improved by 30 min trypsin incubation (0.25% wt/vol trypsin
with 0.02% wt/vol CaCl2 in distilled water), and background staining was
reduced by 15 min incubation with blocking reagent (PerkinElmer, Wellesley,
MA) and 1% wt/vol in phosphate-buffered solution. Subsequent 60 min
incubation with purified rabbit polyclonal IgG against rat TSH (Biogenesis,
Ede, The Netherlands), 1/1000 dilution was followed by incubation with a
biotinylated anti-rabbit second antibody (1/200, 30 min; Vector, Burlingame,
CA) and avidin-biotin complex (Vector) according to instructions of the
manufacturer; both antisera were diluted in the 1% blocking reagent solution.
Immunostaining was completed with incubation with a standard diaminoben-
zidine (Sigma, St Louis, MO) solution for 5 min. Counterstaining was with
hematoxylin (Mayer procedure). Immunostaining intensity was evaluated by
measuring pixel saturation on standardized digital images of comparable areas
in each pituitary, using image analysis software (AnalySIS, Olympus Soft
Imaging Solutions, Mu¨nster, Germany). Saturation profiles were classified
compared with two sample cells, representing low- and high-intensity staining,
and ratios of low/high-intensity pixels were calculated for each image/pituitary.
Immunology/hematology. For hematology, one femoral shaft was flushed
with 4 ml ICP (Impulse Cytophotometer) solution, containing 3.22 g/l
trisodium-citrate-dihydrate, 3.4 g/l sodium-dihydrogenphosphate-dihydrate,
3.87 g/l disodium-hydrogenphosphate-dihydrate, 1.17 g/l citric-acid-
monohydrate, 3.65 g/l dextrose, 4.96 g/l sodiumchloride in demineralized
water, pH 7.4 at 20C. The resulting cell suspension and the collected EDTA
blood were kept at 4C until automated analysis in an ADVIA120 (Bayer,
Leverkusen, Germany) within 4 h. Analysis of the spleen subpopulations (T-
lymphocytes (CD3), T-helper (CD4), cytotoxic T cells (CD8), NK cells
(CD161a), and B-lymphocytes (CD45RA), was done on fixed cell suspensions
prepared of approximately one third of the organ, with a FACS-Calibur (B&D,
Franklin Lakes, NJ) in two separate runs. Numbers of these subpopulations
were calculated from the ratios determined by fluorescence-activated cell sorter
(FACS) analysis, cell counting with the Coulter Counter Z2 (Beckman,
Fullerton, CA), and weights of spleen parts. NK-function test was essentially
performed as described previously (de Jong et al., 1980), with 51Cr-labeled
YAC-1 cells as targets, following an overnight incubation at 37C to remove
adherent cells.
Clinical chemistry. Albumin, alkaline phosphatase, alanine aminotrans-
ferase, total cholesterol, creatinine, glucose, total protein, and urea were
measured routinely as single measurement on an autoanalyzer (Hitachi 912,
Roche Diagnostics, Basel, Switzerland) using standard kits from Roche
Diagnostics. The measurement included hemolytic, icteric, and lipemic indices
to exclude interferences.
TH analysis. Total concentrations of circulating thyroid hormones thy-
roxin T4 and T3 were determined in serum by in-house radioimmunoassays
(RIAs) (Internal Medicine Laboratory, Erasmus Medical Center, Rotterdam)
validated for rats and mice, as described previously (Friedrichsen et al., 2003).
These measurements were done in duplicate RIAs. Within-assay coefficients of
variation amounted to 2–8% for T4 and 2–6% for T3, and between-assay
coefficients of variation were 5–10% for T4 and 8% for T3. Based on structure
differences, no interference of HBCD was expected in this assay.
UDP-glucuronosyltransferase assay. Hepatic microsomal fractions were
prepared by homogenizing liver samples on ice in 3 volumes ice-cold 10mM
Tris-HCl buffer (Sigma Chemicals Co), pH 7.4, containing 0.25M sucrose and
1mM dithiothreitol (DTT, Duchefa Biochemie, Haarlem, NL), using a Potter
tube. The homogenate was centrifuged for 30 min at 12,000 3 g and 0–4C.
The resulting supernatant was centrifuged for 90 min at 105,000 3 g and
0–4C, and the microsomal pellet was resuspended in 2 volumes ice-cold
10mM buffer containing 3mM EDTA and 1mM DTT, pH 7.4. Microsomal
protein levels were determined using BioRad Protein reagent and BSA as
a standard. Hepatic T4-UDP glucuronosyltransferase (UGT) activities were
determined as described previously (Schuur et al., 1997). Briefly, microsomes
(1 mg protein/ml) were incubated for 30 min at 37C with 1lM T4 plus
100,000 cpm 125I-labeled T4 (Amersham, Buckinghamshire, UK), 3.75mM
MgCl2, and 0.125% BSA (Sigma) in the presence or absence (blank) of 5mM
UDP-glucuronyl acid (Sigma) as a cofactor in 200 ll 75mM Tris-HCl, pH 7.8.
Reactions were stopped by the addition of 0.2 ml ice-cold methanol. After
centrifugation, 0.2 ml supernatant was mixed with 0.8 ml 0.1M HCl and
transferred to Sephadex LH-20 minicolumns (Pharmacia, Woerden, NL).
Columns were eluted with HCl to collect free 125I and, subsequently, with
water to collect the glucuronated fraction. Hepatic microsomes from beta-
naphthoflavone (bNF)– and corn oil–exposed rats (Meerts et al., 2000) were
used as positive and negative controls, respectively, throughout all UGT assays
as internal reference. Maximal T4-UGT activities induced by HBCD in this
experiment were approximately 50% of those induced by the internal reference
bNF (2.0 ± 0.4 pmol/min/mg protein).
Apolar retinoid analyses. Apolar retinoids were extracted from liver
homogenates (20% wt/vol in water) using diisopropyl ether and separated on
a Nucleosil C18 5-lm HPLC column using an ethanol:water gradient elution as
described previously (Nilsson et al., 1996). Retinol and retinyl esters were
detected with a JASCO 821-FP fluorescence detector and quantified using
internal and external standards.
Bone analyses. Dissected left femur and tibia were cleaned from soft
tissue and stored in Ringer solution (1 l contains 0.3 g Tris, 0.24 g
CaCl2(H20)2, 0.4 g KCl, and 2.05 ml 1M HCl, pH 7.4) stored in  20C
until analysis. The length of each bone was measured using an electronic
sliding caliper to the nearest 0.01 mm (IP65, Sylvac SA, Crissier, Switzerland).
The bones were scanned using the peripheral quantitative computed tomogra-
phy (pQCT) system (Stratec XCT Research SAþ) with software version 5.50
(Norland Stratec Medizintechnik, GmbH, Birkenfeld, Germany) as described
elsewhere (Stern et al., 2005). Diaphyseal pQCT scans of femur and tibia were
performed at sites distanced 50% of total bone length from the end of the bone
to determine cortical bone parameters. Metaphyseal pQCT scans, at sites
distanced 15% (male and female) of total bone length from the distal end of
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femur and at 12% (male) or 15% (female) from the proximal end of tibia, were
performed to measure total and trabecular bone parameters.
Statistical analysis. Dose-response analysis of effects, based on external
dosing (mg/kg bw) was done using a nested family of purely descriptive
(exponential) models with the PROAST software (Slob, 2002). This method
enables integrated evaluation of the complete data set. From the best curve fit,
indicated by significance at the 5% level, a critical effect dose (CED, also
referred to as benchmark dose, Filipsson et al., 2003) was calculated at a
predefined critical effect size (CES) of 10 or 20% (see Tables 1 and 2 for an
overview). CES is defined as the threshold adverse effect level, determined by
expert judgment for each parameter based on knowledge of the pathophysi-
ology of each effect, including irreversibility or adverse follow-up effects. In
practice, a CES of 10% was defined as the default, considering that this effect
size will cover the hazard for the most sensitive subjects in a population. For
liver weight and immune parameters, a CES of 20% was defined, considering
that lower effect sizes could represent a nontoxic physiologic response. The
analysis was completed with the calculation of a 95% confidence interval (two-
sided), thus enabling the calculation of a 5% lower confidence bound of the
CED estimate. This value may be considered as a benchmark dose at the lower
confidence bound (BMDL) for continuous data. The CED/BMDL ratio was
used as a measure for the (statistical) uncertainty in a data set and, hence, for
validity of the result of the dose-response modeling. As a consequence, in case
of a more than 10-fold difference between CED and BMDL, the data were
considered uninformative. The controls were used as input for the modeling,
although for graphical representation on a log scale, an approximation is used.
BMDL values expressed as external doses were converted to internal doses
(liver concentrations) using the regression equation between external and
internal dose (Tables 1 and 2). For verification, BMDLs were also recalculated
based on internal doses, of which, however, maximal three data points per dose
groups were available (Tables 1 and 2).
The current experimental setup, with relatively few replicates per dose
group, is not suitable for comparing individual dose groups due to limited
statistical power. However, some parameters, which were targeted at discerning
an overall difference rather than a dose-response, were analyzed using
conventional statistical tests. These included Fisher exact test (for distribution
of histological scores of liver basophilia between controls and exposed
specimen), two-way ANOVA (for variance of TSH immunostaining using
dosing and gender as covariates), and a Student t-test (for comparing glucose
concentrations between all males and all females).
RESULTS
In Life Observations
Two male rats died from erroneous administration on
exposure day 4. They were replaced since these animals were
from a single dose group (3 mg/kg bw). Another rat (female,
dose group 0.3 mg/kg bw) died from the same cause in the
second week of exposure; this animal was not replaced. Two
animals showed transient irritation of both eyes and three other
animals had transient and limited skin irritations. These
aberrations were not considered to be related to the exposure.
There were no further clinical anomalies, dosing was well
tolerated. All animals in all dose groups showed normal feed
consumption. There were no effects on body growth during the
exposure period (Supplementary Data Table 1).
Internal HBCD Concentrations
Analysis of HBCD-a and -c in the liver showed a dose-
dependent increase with a plateau at the three highest doses
(Fig. 1). Remarkably, the HBCD concentrations in the liver
were higher in females than in males over the entire dose range
(on average 5.2 times), and all females in the control group also
had low levels of HBCD, whereas HBCD was below the limit
of detection in control males. The average ratio c/a, which was
approximately 8.1 in the administered technical mix, appeared
to be 2.9 in females and 1.9 in males and decreased with dose in
both sexes; at low doses, there was a higher contribution of the
c enantiomer, while at higher doses the ratio equalized or re-
versed. Similarly, the higher concentration of HBCD in female
compared to male livers was mainly due to contributions of the
c enantiomer at low and the a enantiomer at high doses. The
lipid fraction in livers was not different between females and
males, nor were there differences between dose groups.
Analysis of fat samples of two animals of each sex in the
10 mg/kg bw dose groups revealed average HBCD values of
379.5 and 84.9 mg/kg retroperitoneal fat tissue in females and
males, respectively, that is, 2.4 and 1.4 times higher than in
liver lipid (not shown).
Sperm Analysis
Sperm collected from the epididymis during necropsy had
similar characteristics in all dose groups (data available in
Supplementary Data Table 2).
Organ Weights
There was a significant dose-dependent weight increase of
the pituitary, the thyroid, and liver in females only. In males,
there was only a decrease in thymus weight (Tables 1 and 2;
Supplementary data Table 2). Dose-responses of spleen and
kidney weights of female animals were too limited for
calculation of BMDLs.
The applied CES and corresponding BMDLs, both based on
external doses and internal concentrations for these and other
variables, are shown in Tables 1 and 2; details of weights of all
organs are given in Supplementary Data Table 2. The deduction
of a CED at a predefined CES is illustrated in Figure 2.
Histopathology
Histopathology of the thyroid showed that in HBCD-
exposed females, thyroid follicles were smaller, depleted, and
had activated, hypertrophied epithelium (Fig. 3A). Histopatho-
logical grading of the thyroid activation was based on
assessment of follicle cell height, cellular vacuolization, and
size of the nucleus, most of which showed a dose-related
increase in both sexes, and scoring of follicle size, which
showed a dose-related decrease in males (Table 3). Cell height
and nuclear size were most sensitive, with initiation of the ef-
fect (a progression from slight to moderate activation, i.e., size)
at intermediate doses, whereas effects in follicle size and
cytoplasmic vacuolization only appeared at the high end of the
dose range. In males, control thyroids were already moderately
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TABLE 1
Significant HBCD-Induced Dose-Response Effects in Female Rats
Organ weights Plasma chemistry Liver chemistry Total bonea Trabecular bonea
HBCD dose
mg/kg bw n
Pituitary
(mg)
Thyroid
(mg)
Liver
(g) n
ALP
(U/l)
CHOL
(mmol/l)
GLU
(mmol/l)
Total
protein (g/l)
Albumin
(g/l) n
TT4
(nmol/l)
TT3
(nmol/)
T4-UGT
(pmol/min/mg
protein)b
Retinyl
palmitate
(nmol/g
liver)
Retinol
(nmol/g
liver)
Sum
retinoids
(nmol/g
liver) n
Femur Femur Tibia
Area
(mm2)
Mineral
content
(mg/mm)
Mineral
density
(mg/cm3)
0 5 5 ± 1 17 ± 2 9.7 ± 1.0 5 4.7 ± 2.9 1.8 ± 0.2 9.8 ± 0.9 56.1 ± 2.0 42.0 ± 1.6 5 41.3 ± 2.6 0.91 ± 0.10 0.56 ± 0.23 1720 ± 297 19.1 ± 2.9 1987 ± 338 3 16.1 ± 1.5 10.5 ± 0.5 228 ± 34 199 ± 45
0.3 4 12 ± 1 18 ± 2 8.9 ± 1.1 3 3.1 ± 2.8 1.7 ± 0.1 9.6 ± 1.2 56.9 ± 2.2 43.2 ± 1.3 4–5 41.9 ± 3.1 0.84 ± 0.15 0.61 ± 0.15 1831 ± 224 28.7 ± 12.5 2138 ± 234 3 14.9 ± 0.9 10.2 ± 1.1 262 ± 34 226 ± 53
1 5 11 ± 3 22 ± 4 8.6 ± 1.3 3 4.7 ± 2.5 1.7 ± 03 9.8 ± 1.0 56.4 ± 1.8 42.6 ± 1.4 5 40.2 ± 7.3 0.88 ± 0.12 0.53 ± 0.17 1690 ± 301 26.2 ± 7.1 1964 ± 349 4 13.7 ± 0.6 9.5 ± 0.6 231 ± 40 199 ± 24
3 5 13 ± 2 15 ± 4 9.5 ± 0.4 3 3.7 ± 2.1 1.9 ± 0.3 10.3 ± 1.2 56.3 ± 0.7 42.3 ± 1.1 5 37.2 ± 4.7 0.81 ± 0.11 0.43 ± 0.09 1542 ± 236 24.9 ± 2.7 1797 ± 280 5 14.4 ± 0.7 9.2 ± 0.7 219 ± 20 186 ± 23
10 5 11 ± 3 18 ± 3 8.9 ± 0.6 3 2.3 ± 1.2 1.6 ± 0.2 9.4 ± 0.4 56.8 ± 2.4 42.1 ± 1.7 5 38.6 ± 1.7 0.80 ± 0.09 0.57 ± 0.14 1368 ± 98 22.8 ± 1.2 1601 ± 103 3 14.5 ± 0.9 9.5 ± 1.1 211 ± 45 201 ± 70
30 5 8 ± 2 35 ± 17 11.0 ± 1.0 4 2.4 ± 0.3 1.9 ± 0.3 9.8 ± 1.1 59.2 ± 3.1 42.6 ± 2.8 4–5 38.0 ± 6.1 0.74 ± 0.15 0.74 ± 0.22 1157 ± 122 17.1 ± 3.5 1354 ± 135 3 15.5 ± 0.4 9.9 ± 0.4 248 ± 10 181 ± 33
100 5 13 ± 1 27 ± 7 13.0 ± 0.5 4 2.7 ± 1.6 2.4 ± 0.2 8.7 ± 0.9 64.1 ± 1.3 45.6 ± 1.1 4–5 35.8 ± 5.2 0.92 ± 0.20 1.39 ± 0.27 1152 ± 162 17.0 ± 5.0 1361 ± 169 3 16.2 ± 1 10.4 ± 0.8 228 ± 22 195 ± 29
200 5 13 ± 2 26 ± 3 11.6 ± 0.6 3 2.4 ± 2.7 1.8 ± 0.2 8.1 ± 1.8 61.0 ± 3.6 44.2 ± 2.6 5 30.4 ± 5.9 0.82 ± 0.13 0.99 ± 0.43 1193 ± 186 15.4 ± 1.3 1386 ± 205 3 15.7 ± 0.7 11.1 ± 0.5 265 ± 20 251 ± 12
CES (%) 10 10 20  10 10  10 10 10  10 10 10  10  10  10 10 10 10 10
CED
(mg/kg bw)
50.6 3.4 29.9 33.9 23.6 100.0 194.3 316.8 76.1 — 14.5 3.0 16.0 3.1 > 200 134.6 139.3 91.1
BMDL
(mg/kg bw)
29.9 1.6 22.9 18.9 7.4 70.8 142.7 197.5 55.5 4.1 1.6 4.8 1.6 129.8 86.7 69.9 49.3
Ratio
CED/BMDL
1.7 2.1 1.3 1.8 3.2 1.4 1.4 1.6 1.4 3.5 1.9 3.4 1.9 1.8 1.6 2.0 1.8
Maximum
response
(% compared
to control)
More
than
þ 41c
þ 61 þ 36 More
than
 45.3c
þ 19.9 More
than
 17.1c
þ 11.1 þ 6.1 More
than
 23.5c
þ 121  33.7  30.8  33.6 þ 9 More
than
þ 15c
More
than
þ 18c
More
than
þ 31c
BMDL (ID)
(lg/g liver
lipid,
convertedd)
223 43 192 172 102 361 534 640 315 73 43 80 43 506 504 358 295
BMDL (ID)
(lg/g liver
lipid,
recalculatede)
— 39 112 — 121 253 209 267 209 — 64 — — — 149 148 141 130
Note. Figures are average ± SD of n replicates per dose group, CED values indicate critical effect dose at the given critical effect size (CES). ALP, alkaline phosphatase; CHOL, cholesterol; GLU,
glucose; T4-UGT, T4-uridine diphosphate glucuronyl transferase; —, no significant dose-response or ratio CED/BMDL (ID) above 10.
aMeasured at femur and tibia metaphysis.
bA similar dose-response is observed when activities are expressed per min per gram liver.
cNo plateau reached within the applied dose range.
dFor conversion external dose (ED)-internal dose (ID), the regression equation ID ¼ 33377 3 ED 0.5587 (with R2 ¼ 0.79) was used.
eFor recalculations, which were applied for verification of the converted IDs, dose-responses were directly analyzed using ID as X-variable; differences between converted and recalculated BMDL
(ID) values are probably mainly due to different size of the data sets; only three or even less animals per dose group were available for recalculation, with subsequent larger confidence interval variation
(particularly with bone parameters). For this reason, the recalculated BMDL (ID) values are generally below the converted BMDL (ID) values, and the converted BMDL (ID) values should be considered
more reliable.
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TABLE 2
Significant HBCD-Induced Dose-Response Effects in Male Rats
Organ weights Spleen absolute cell numbers (3 107)) Plasma chemistry Liver
HBCD dose n
Thymus
(g) n
Total cells
per spleen
CD4
(Th)
CD161a
(NK) n
CHOL
(mmol/l)
GLU
(mmol/l)
Total
protein (g/l)
Albumin
(g/l) n
TT4
(nmol/l)
TT3
(nmol/l)
T4-UGT
(pmol/min/mg
protein)a
0 5 0.47 ± 0.08 4 48.7 ± 10.5 14.0 ± 4.7 4.8 ± 1.2 5 2.08 ± 0.20 10.6 ± 1.1 56.4 ± 2.1 39.2 ± 1.0 5 40.2 ± 3.6 0.81 ± 0.06 0.36 ± 0.05
0.3 5 0.45 ± 0.08 1 49.6 15.2 3.8 3 2.13 ± 0.31 10.4 ± 3.2 58.1 ± 2.9 39.1 ± 0.7 4–5 40.4 ± 5.0 0.84 ± 0.14 0.44 ± 0.15
1 5 0.52 ± 0.17 2 47.1 ± 15.4 13.3 ± 4.8 3.6 ± 0.1 3 2.10 ± 0.23 10.3 ± 2.6 58.6 ± 2.2 39.7 ± 1.9 5 40.6 ± 5.3 0.85 ± 0.16 0.40 ± 0.14
3 5 0.47 ± 0.07 1 44.4 11.4 4.6 3 1.74 ± 0.30 10.9 ± 1.8 58.1 ± 1.5 40.1 ± 0.3 5 49.4 ± 7.2 0.89 ± 0.04 0.69 ± 0.37
10 4 0.50 ± 0.09 2 39.4 ± 3.8 10.5 ± 0.9 4.1 ± 1.2 3 2.01 ± 0.23 10.9 ± 2.5 57.6 ± 2.0 38.8 ± 1.2 5 43.3 ± 1.3 0.97 ± 0.16 0.60 ± 0.24
30 5 0.37 ± 0.06 1 29.7 9 2.7 4 2.31 ± 0.41 10.5 ± 1.5 60.1 ± 1.2 39.2 ± 1.6 4–5 41.9 ± 4.6 0.90 ± 0.13 0.73 ± 0.26
100 5 0.42 ± 0.09 1 37 11.2 2.9 4 1.99 ± 0.39 9.7 ± 2.6 61.4 ± 1.7 40.8 ± 1.8 4–5 35.4 ± 4.2 0.82 ± 0.06 0.99 ± 0.41
200 5 0.38 ± 0.13 2 35.8 ± 1.1 10.0 ± 2.0 2.6 ± 0.1 3 1.63 ± 0.19 8.4 ± 1.2 59.6 ± 3.6 40.6 ± 1.8 5 41.4 ± 3.5 0.89 ± 0.05 0.88 ± 0.45
CES (%) 20 20 20 20 10 10 10 10 10 10 10
CED (mg/kg bw) 176.6 9.8 1.9 12.6 102.9 98.1 > 200 > 200 — — 1.1
BMDL (mg/kg bw) 104.2 1.7 0.3 6.3 65.9 57 > 200 > 200 0.1
Ratio CED/BMDL 1.7 5.8 6.3 3 1.6 1.7 1.7 1.8 11
Maximum response
(% compared to control)
 20  28  33  41 Less than
 21.2b
Less than
 19.7b
5.2 More than
þ 3.8b
106
BMDL (ID) (lg/g liver
lipid, convertedc)
113 8.5 2.9 19 85 77 —
BMDL (ID) (lg/g liver
lipid, recalculatedd)
52 — — — — — 83 — — — 21
Note. Figures are average ± SD of n replicates per dose group. CHOL, cholesterol; GLU, glucose; T4-UGT, T4-uridine diphosphate glucuronyl transferase; —, no significant dose-response or ratio
CED/BMDL (ID) above 10.
aA similar dose-response is observed when activities are expressed per min per gram liver.
bMeasured at femur and tibia metaphysis.
cThe regression equation for conversion external dose (ED)-internal dose (ID) ID ¼ 6101 3 ED 0.6276 (with R2 ¼ 0.38) was used.
dFor recalculations, which were applied for verification of the converted IDs, dose-responses were directly analyzed using ID as X-variable; differences between converted and recalculated BMDL
(ID) values are probably mainly due to different size of the data sets; only three or even less animals per dose group were available for recalculation, with subsequent larger confidence interval variation
(particularly with spleen parameters). For this reason, the recalculated BMDL (ID) values are generally below the converted BMDL (ID) values, and the converted BMDL (ID) values should be
considered more reliable.
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activated, and changes to advanced activation were therefore
less obvious. There were no indications of hyperplasia.
Immunohistochemical detection of TSH in the pituitary was
done to elucidate whether activation of the thyroid epithelium
was associated with increased expression of this stimulating
hormone. Comparison of top dose animals with control animals
showed a significantly increased ratio between high- and low-
intensity immunostaining thyrotropic cells (Fig. 3B). When
comparing dosed and control animals per gender, the effect was
only significant in females, consistent with the increase of
pituitary weight in females.
In the liver, HBCD-exposed specimen of both sexes could be
discerned on the basis of intense basophilia, specifically in
periportal zones (Fig. 3C) to an accuracy of 60–80% by
repeated blind scoring (not statistically significant, Fisher exact
test). This visual effect is suggestive of endoplasmatic re-
ticulum induction, compatible with increased synthetic activity,
and is in line with the increased liver weights in females. There
were no further apparent HBCD exposure associated changes
in the liver, nor in the other organs assessed for histopathology,
after analysis of the control and (sub-) top dose (n ¼ 5 per sex
per group; Supplementary Data Table 3). Inflammation in
Langerhans islets was observed throughout all groups, in-
dependent of dosing. This insulitis was more severe in males
than in females and associated with a gender difference
regarding glucose concentrations (see below) but not related
to exposure (not shown).
Immunology/Hematology
FACS analysis of immune cell populations in the spleen,
which was only performed in male animals, revealed reduced
total spleen cell count and counts of T-helper and NK cell
subpopulations (Tables 1 and 2; Supplementary Data Table 4).
Fractions of these cells did not change because counts of other
subpopulations also declined, although not significantly. Cy-
totoxic activity of NK cells was also not affected. There were
no effects on blood or bone marrow white blood cell popula-
tions (Supplementary Data Table 5). In hematological param-
eters, which were also only measured in males, there was a
marginal decrease of the mean red blood cell volume, with a
concomitant increase of mean erythrocyte hemoglobin con-
centration (Supplementary Data Table 6). Both changes were,
however, below the CES.
Clinical Chemistry
Chemical analysis of plasma showed that female rats had
decreased concentrations of alkaline phosphatase and glucose
and increased cholesterol and total protein/albumin. Males had
decreased cholesterol, increased total protein/albumin, and de-
creased glucose, all in a significant dose-dependent way (Tables 1
and 2; Supplementary Data Table 7). Plasma glucose concen-
trations were higher in males compared to females (10.2 ±
2.1 in 40 males and 9.5 ± 1.2 mmol/l in 38 females), a nearly
significant difference (p ¼ 0.079).
Thyroid Hormones and T4-UGT
Measurement of thyroid hormones showed a dose-dependent
decrease in total T4 (TT4) in females only (Tables 1 and 2;
Supplementary Data Table 8); there were no effects on total T3
FIG. 1. Sum HBCD a and c in liver of female and male rats, after exposure
to 0.3–200 mg/kg bw of technical mix for 28 days. Concentrations are
expressed per gram of lipid on a logarithmic scale. There is a dose-dependent
increase in both sexes up to a plateau in the three highest doses. Females tend to
have higher concentrations than males. Averages are based on measurement of
three animals per group; error bars indicate SD. For correlation equations, see
Tables 1 and 2.
FIG. 2. Dose-response analysis illustrated with circulating TT4 in female
rats. Method and parameters describing the curve were explained in Slob
(2002). In this model, parameter a is the background level and b reflects the
efficacy of exposure (slope). Log likelihood is used to assess to what extent the
described curve deviates from no effect (y ¼ a). CES, critical effect size, for
TT4 set at 10% (horizontal dotted arrow); a corresponding critical effect dose
(CED) is represented by the vertical dotted arrow. Exposure dose (x-axis) is on
a logarithmic scale.
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(TT3) levels. In both male and female liver, a dose-dependent
increase of T4-UGT activity was found (Tables 1 and 2;
Supplementary Data Table 8). The BMDL was lower for male
than for female rats (0.1 vs. 4.1), however, the high CED/
BMDL ratio for T4-UGT in males implies high statistical
uncertainty due to high variation of the data set, that is, general
scatter (Tables 1 and 2); therefore, the BMDL for this para-
meter is considered not valid.
Liver Retinoids
Marked dose-related decreases in apolar liver retinoid
concentrations were observed in female rats (Tables 1 and 2;
Supplementary Data Table 9). The decreases were parallel to
the dose-related increase in liver weight (Tables 1 and 2; Sup-
plementary Data Table 3). No effect on the apolar liver retinoid
concentrations was seen in male rats (Table 9). The total
contents of apolar retinoids in the liver were not affected by
HBCD at any dose neither in female nor in male rats (Table 9).
Bone Parameters
In bone, the most consistent observation was an increase in
mineral density of trabecular bone at femur and tibia meta-
physis in female rats (Tables 1 and 2; Supplementary Data
Table 10). Further changes at the femur metaphysis of female
FIG. 3. (A) Histology in the central thyroid of female rats, control (left panels) and after 28 days of exposure to 100 mg/kg bw HBCD (right panels) at low (top)
and high (bottom) magnification. In the exposed sample, follicles are smaller or even depleted, the intrafollicular colloid (c) stains more faintly; cell height is
increased (compare yellow arrows), nuclear size increased, and cells are more vacuolated (black arrow). All effects are illustrated at a moderate degree (see Table 3).
(B) Morphometrical analysis of immunostained thyrotropic cells (top). The ratio between high and low saturation of TSH immunostaining was significantly increased
in females exposed to the highest dose HBCD (p¼ 0.043, t-test). In the ANOVA, HBCD exposure accounted significantly for total variance (p¼ 0.038), while there
was no significant effect of gender, nor is there interaction between variables. For both groups of female pituitaries n ¼ 5 and n ¼ 4 for both male groups. The
microphotograph (bottom) is an image sample used for the morphometry with thin and thick arrows indicating low- and high-intensity staining cells. (C) Liver
microphotographs of a control (left) and a HBCD (right)-exposed female (100 mg/kg bw), illustrating increased basophilia in periportal zones after exposure (dark
staining areas). A basophilic staining hepatocyte is indicated with an arrow, false color inserts show that there is more basophilia (black) in the HBCD-exposed liver.
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rats were increased total bone area and increased total bone
mineral contents. There were no changes in any of the bone
parameters in male rats.
DISCUSSION
The BFR HBCD is a potentially persisting and bioaccumu-
lating compound, of which low but significant exposure levels
are found in humans (Fa¨ngstro¨m et al., 2006; Ryan et al.,
2006). HBCD is suspected to interfere with the endocrine
system (Legler and Brouwer, 2003). For these reasons, it was
tested in a subacute toxicity study, enhanced for endocrine and
immune endpoints.
The daily gavage dosing resulted in dose-dependent liver
concentrations of the compound, indicating bioavailability. The
higher HBCD concentrations in females are consistent with
results from a 90-day study in rats (Chengelis, 2001; cited in
KEMI, 2003) and possibly due to a faster elimination in male
compared to female rats (Yu and Atallah, 1980; cited in KEMI,
2003). The excreted HBCD in that study, both in the feces and
in the urine, was probably completely metabolized, indicating
complete absorption of the orally dosed compound. Since
activity of all assessed metabolizing enzymes, CYP1A1,
CYP2B, CYP3A (Germer et al., 2006), and T4-UGT (Tables 1
and 2) was lower or comparable in males compared to females
(background and exposed), other mechanisms may play a role.
The same mechanisms can also explain why HBCD was
recovered from control female but not male animals, assuming
that these control animals received traces of the compound,
presumably, through the standard feed or from ambient
contamination. In the 90-day study cited above, the HBCD
concentrations in adipose tissue were 4–5 times higher than the
concentrations in liver lipid in top dose animals in our study.
Although comparison between these two studies is hampered
by differences of preparations (acetone assisted solution in our
study) and top doses (five times higher in the Chengelis study),
a limited analysis in our study also showed higher concen-
trations in adipose tissue than in liver lipid.
The c/a HBCD isomer ratio in this study differed from the
pattern in wildlife where a HBCD dominates (Zegers et al.,
2005). On the other hand, even the highest c/a ratio in our rats
was far lower than the c/a ratio of the technical preparation
used for exposure. This is in line with a higher susceptibility of
the c isomer to biodegradation compared to the a isomer in
CYP2B-induced rat liver microsomes (Zegers et al., 2005). The
decreasing c/a ratio with increasing dose can then be under-
stood as intensified biotransformation of the c isomer with
increasing dose, whereas relatively more biotransformation-
resistant a isomer will accumulate. This effect may be enhanced
by the induction of CYP2B (Germer et al., 2006). In this
perspective, the different isomer ratios in our rats and in wildlife
are most likely due to differences in exposure dose and duration.
The most marked HBCD dose-related effects were on the
TH axis, including decreased TT4, increased immunostaining
for TSH in the pituitary, increased weight/activation of the
pituitary and the thyroid glands, and induction of T4-UGT in
the liver. All these effects were restricted to females, which is
in line with the higher HBCD liver concentrations in females
versus males, although contrasting with observations in a 90-
day study by Chengelis (Chengelis, 2001; cited in KEMI,
2003), which showed decreased TT4, increased serum TSH,
and thyroid gland activation in both sexes. Decreased TT4 can
be considered as a relative insufficiency of the feedback
(activation of pituitary/thyroid glands), that is, the imposed
stress is beyond the exposure dose that can be adequately
counterbalanced by an activated feedback system (McDermott
and Ridgway, 2001). On the other hand, the feedback was suf-
ficient to maintain physiological levels of the biological active
TT3 in exposed animals, but even under these circumstances,
decreased plasma TT4 levels can induce hypothyroidy-like
effects, because plasma T4 is a source for intracellular T3
through deiodination (Escobar del Rey et al., 1989).
The increased TSH immunostaining detected in the pituitary
is likely an indicative of increased levels of circulating TSH in
exposed animals, as measured in the 90-days study (Chengelis,
2001; cited in KEMI, 2003). The increased weight of the
pituitary must be due to indiscernible diffuse cellular hyper-
trophy and/or hyperplasia since no robust (clonal) changes
were observed. Since, probably, only a limited number of the
many cell populations of the pituitary are affected in a specific
way, the detected slight weight increase of the pituitary may be
symptomatic of a relatively strong effect in a single sub-
population, probably mainly the thyrotropic cells. The higher
TABLE 3
Doses of Progression for Histological Stages in the Thyroid
Females Males
Background
stage
CED for
progression to
next stage
(mg/kg bw)
Background
stage
CED for
progression to
next stage
(mg/kg bw)
Cell height 1 47 2 —
Nuclear size 1 25 2 39
Vacuolization 1 177 2 90
Follicle size 1 — 1 199
Note. Thyroids of all available animals (n ¼ 38, females; n ¼ 36 males)
were evaluated for the histological parameters of the first column. Stages
indicated size (cell, nucleus, and follicles), or degree of vacuolization (number
and size of discernible vacuoles). CEDs are the critical effect doses in mg/kg
body weight at which the average thyroid progresses to a further stage in
a staging range 0–3, that is, reference, slight, moderate, and severe. Reference
and moderate degree of effect in all four parameters is illustrated in Figure 3.
For all four endpoints, there is a maximum progression of one stage. Male
samples have higher background stages than female samples. Effects in cell
height and nuclear size are initiated at intermediate doses (and reach a plateau
at the end of the dose range). Effects in follicle size and cytoplasmic
vacuolization are initiated at high doses.
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background activity observed in male thyroid histology,
compared to control females, is in line with higher levels of
circulating TSH in males than in females (Capen, 1997). The
associated higher sensitivity for induction of proliferative
lesions is not relevant here since these were not observed.
One of several ways by which HBCD could induce hypo-
thyroxinemia is through evoking a detoxification response in
the liver, which concomitantly affects T4. Indeed, HBCD
treatment led to induction of CYP2B and CYP3A (Germer
et al., 2006). This is in line with the induction of UGT described
here since there is coexpression of and functional cooperation
between P450 and UGT enzymes (Ishii et al., 2005). The
detoxification activity was stronger in female compared to male
rats, consistent with the suggested histopathologic activation of
the liver and increased liver weights in female rats, the latter
also observed in a similar study (Chengelis, 1997; cited in
KEMI, 2003). The higher sensitivity of females versus males for
HBCD exposure could be enhanced by the lower binding
capacity of TTR in female compared to male rats (Emerson
et al., 1990). Since TTR is the major TH carrier protein in the
adult rat (Schussler, 2000), T4 might thus be more available for
metabolization in females compared to males.
Other mechanisms which can induce hypothyroxinemia, such
as direct interaction of HBCD with TH synthesis, or activation
of other metabolizing enzymes (e.g., deiodinases, sulfotrans-
ferases) or cellular TH uptake were not explored in this study.
Multiple mechanisms can be responsible for the observed
effects on plasma parameters, including interaction of HBCD
with many hormone receptors (Hamers et al., 2006). Further-
more, a physiologic relationship with the observed TH changes
may possibly play a role, in view of the regulating potential of
THs on metabolism. Specifically, associations between TH dis-
ruption and disregulation of metabolism of lipids/cholesterol
(Fleischman and Shumaker, 1942), of serum proteins (Larsen
and Davies, 2002), and of plasma glucose levels (Chidakel
et al., 2005) are known. Some of these associations, partly also
observed in a previous study (Chengelis, 2001; cited in KEMI,
2003), are gender specific. We cannot exclude that the effects
on plasma glucose are biased by the insulitis which was present
throughout the entire population of this experiment (and in
other animals from the same source).
In general, decreased alkaline phosphatase in the plasma, as
observed in the female rats, can be a marker of decreased
activity of the liver or of osteoblasts. Both, however, appeared
to be activated (increased liver weight, liver histopathology,
and increased bone density). On the other hand, osteoblast
alkaline phosphatase expression, which is TH dependent
(Milne et al., 1998), could possibly be suppressed by HBCD
through activation of TH-mediated effects (Hamers et al., 2006).
The observed changes in the immune system (weight of
spleen and thymus, spleen cellularity) are considered relevant
because each imbalance in this system may reduce the homeo-
static capacity of the individual. The effects on splenocyte
counts should, however, be interpreted with caution due to
small sample size and high CED/BMDL ratios, implicating
statistical uncertainty. There is no unequivocal explanation for
these effects, which may be related to a potential direct inter-
action of HBCD with steroid hormone or TH systems, the latter
in view of the effects that TH can have on lymphocyte
functions (Ong et al., 1986).
The dose-dependent decrease of liver apolar retinoid con-
centrations in female rats probably reflects the dose-related
increase in liver weight of these animals since there was no
effect of HBCD on the total liver contents of apolar retinoids.
Hepatic retinoid reduction has been proposed as an AhR-
mediated response (Nilsson and Hakansson, 2002). Thus, the
lack of retinoid effect, suggesting that HBCD does not activate
the AhR, is consistent with the unaffected hepatic expression of
CYP1A1/hepatic ethoxyresorufin-o-deethylase activity (Germer
et al., 2006).
Increased trabecular bone mineral density was observed at
femur and tibia metaphysis in female rats, but there was no
effect of HBCD on cortical bone at the diaphysis. This suggests
that trabecular bone is more sensitive to the perturbations by
HBCD compared to cortical bone, which may be related to the
higher metabolic activity and turnover rate of trabecular
compared to cortical bone (Ott, 2002). Since TH are involved
in normal skeletal development, linear growth and the main-
tenance of adult bone mass (Bassett and Williams, 2003), the
effect of HBCD in bone may be related with the observed
hypothyroxinemia, supported by the occurrence of both effects
in female rats only. Other mechanisms of action of HBCD can,
however, not be excluded.
Evaluation
According to United States Environmental Protection
Agency, adverse rodent noncancer thyroid effects due to chem-
ically induced thyroid-pituitary disruption should be consid-
ered relevant to humans (Hill et al., 1998). In the current study,
HBCD evoked a sequence of events in the TH system, specif-
ically, in female rats. Apparently, these effects did not exceed
the limits of homeostasis, in view of unaffected levels of circu-
lating T3, but decreased plasma TT4 levels may well cause
hypothyroidy-like effects. The initiating event is probably
activation of liver enzymes (induction of T4-UGT at a BMDL
of 4.1 mkd), resulting in increased liver weight at 22.9 mkd)
with increased TH turnover (decreased TT4 at 55.5 mkd) and a
feedback reaction in the pituitary (increased weight at 29 mkd,
increased immunostaining intensity of TSH) and the thyroid
gland (increased weight at 1.6 mkd, follicle cell activation at 25
mkd) as a consequence. Additional events, which may be sec-
ondary to changes in the TH system, include effects on plasma
chemistry (notably, increased cholesterol at 7.4 mkd), bone
parameters (49 mkd and higher), and spleen parameters (de-
creased splenocyte counts 0.3–6.3 mkd, only assessed in males).
Overall, female rats appear to be more sensitive to HBCD
exposure than male rats, and a BMDL for adversity of HBCD,
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based on the most sensitive parameter, should be defined at
1.6 mg/kg bw (equivalent to 43 lg HBCD/g liver) for the 10%
increase of the thyroid weight. This is well below the
previously proposed lowest observed adverse effect level
(LOAEL) of 100 mkd based on increased liver weight and
disturbed TH system (Chengelis, 2001; cited in KEMI, 2003),
and in the range of the LOAEL of 0.9 mkd based on behavioral
effects in mice (Eriksson et al., 2006). Combined with recent
exposure data in human breast milk, indicating HBCD levels
which are at least four orders of magnitude below this BMDL
(Fa¨ngstro¨m et al., 2006; Ryan et al., 2006), this study does not
support a major health risk of HBCD for humans.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.
oxfordjournals.org/. Supplementary tables are provided to
show average values with SD of body and organ weights and
cauda epididymis sperm characteristics at necropsy, and a sum-
mary of histopathologic observations. For male rats only, aver-
age values with SD are provided of spleen subpopulations and
NK activity, white cells in blood and bone marrow, and red
blood cell parameters. Similar tables show average values with
SD of clinical plasma chemistry, thyroid hormones and T4-
UGT, retinoids in liver, and bone parameters of femur and tibia.
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